Goeldner, Rainer-Georg
Boehringer Ingelheim (Germany)
4 papers on CoChatORCID 0009-0001-2918-8946
Most cited papers
- Verified
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases
Cited by 2,403
- Verified
The natural history of progressive fibrosing interstitial lung diseases
Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases
Cited by 293
- Verified
Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., & Stopfer, P. (2013) · Clinical Pharmacokinetics
HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism
Cited by 94
- Verified
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
Schnell, D., Buschke, S., Fuchs, H., Gansser, D., Goeldner, R.-G., Uttenreuther-Fischer, M., Stopfer, P., Wind, S., Petersen-Sylla, M., Halabi, A., et al. (2014) · Cancer Chemotherapy and Pharmacology
Pharmacogenetics and Drug MetabolismHER2/EGFR in Cancer Research
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free